Lantheus (NASDAQ:LNTH) Share Price Breaks Above Fifty Day Moving Average – Here’s Why

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $100.25 and traded as high as $100.50. Lantheus shares last traded at $100.32, with a volume of 771,628 shares changing hands.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Mizuho cut shares of Lantheus from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $115.00 to $109.00 in a report on Tuesday, October 13th. B. Riley Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Leerink Partners set a $102.50 price objective on shares of Lantheus in a research report on Monday, August 3rd. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Finally, TD Cowen downgraded shares of Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the stock from $110.00 to $102.50 in a research note on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $107.44.

Lantheus Price Performance

The firm has a market capitalization of $6.55 billion, a P/E ratio of 24.23 and a beta of -0.06. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The stock’s fifty day simple moving average is $100.25 and its 200 day simple moving average is $91.01.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. The firm had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.57 EPS. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 4.54 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LNTH. Western Wealth Management LLC purchased a new position in Lantheus in the 1st quarter worth $25,000. Bessemer Group Inc. lifted its position in Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 354 shares during the period. USA Financial Formulas purchased a new stake in Lantheus during the 3rd quarter valued at about $41,000. Allworth Financial LP purchased a new stake in Lantheus during the 2nd quarter valued at about $49,000. Finally, Farther Finance Advisors LLC grew its stake in Lantheus by 122.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 306 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.